IMforte Trial Results and Efficacy Data

Dr. Joshua Sabari introduces the program on evolving maintenance and sequencing strategies in extensive-stage small cell lung cancer (ES-SCLC), joined by Dr. Anne Chiang from Yale, Dr. Jacob Sands from Dana-Farber, Dr. Misty Shields from Indiana University, and Dr. Ticiana Leal from Emory University's Winship Cancer Institute.

Dr. Chiang presents the IMforte trial results, representing the first positive maintenance study in SCLC with both progression-free survival (PFS) and overall survival (OS) benefits. Patients completing induction chemotherapy with atezolizumab were randomized to lurbinectedin plus atezolizumab versus atezolizumab alone, demonstrating OS improvement from approximately 10 to 13 months, representing a 3-month benefit.

She emphasizes that this benefit reflects time from randomization into maintenance, requiring addition of the 3.2-month induction period for complete context. The trial experienced approximately 25% attrition between initial enrollment and randomization, as patients required ECOG performance status 0 to 1 for maintenance eligibility. Notably, the trial excluded patients with brain metastases.

For patients tolerating induction well and maintaining good performance status who wish to pursue aggressive treatment, this maintenance approach represents an excellent option according to Dr. Chiang's clinical practice.

Dr. Sands addresses the toxicity profile, noting that although myelosuppression (anemia, neutropenia, thrombocytopenia) represented the most common grade 3 to 4 adverse events, fatigue and nausea were typically low-grade and temporary. He emphasizes individualized risk-benefit discussions with patients, ensuring continued trial eligibility for subsequent therapy lines, and recognizing when patients aren't recovering adequately between cycles, requiring treatment discontinuation in rare cases.